Targeting TLR/IL-1R Signalling in Human Diseases by Loiarro, Maria et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2010, Article ID 674363, 12 pages
doi:10.1155/2010/674363
Review Article
TargetingTLR/IL-1RSignallinginHumanDiseases
Maria Loiarro,1,2 Vito Ruggiero,3 andClaudioSette1,2
1Department of Public Health and Cell Biology, University of Rome “Tor Vergata”, 00133 Rome, Italy
2Laboratory of Neuroembryology, Fondazione Santa Lucia, Istituto Di Ricovero e Cura a Carattere Scientiﬁco (IRCCS),
00143 Rome, Italy
3Department of Immunology (Bldg. LABIO), R&D Sigma-tau Industrie Farmaceutiche Riunite S.p.A, Via Pontina km 30.400,
00040 Pomezia (RM), Italy
Correspondence should be addressed to Vito Ruggiero, vito.ruggiero@sigma-tau.it and Claudio Sette, claudio.sette@uniroma2.it
Received 1 December 2009; Revised 16 January 2010; Accepted 17 January 2010
Academic Editor: Natalija Novak
Copyright © 2010 Maria Loiarro et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The members of Toll-like receptor/Interleukin (IL)-1 receptor (TLR/IL-1R) superfamily play a fundamental role in the immune
response.Thesereceptorsdetectmicrobialcomponentsandtriggercomplexsignallingpathwaysthatresultinincreasedexpression
of multiple inﬂammatory genes. On the other hand, an aberrant activation of TLR/IL-1R signalling can promote the onset of
inﬂammatory and autoimmune diseases, raising the interest in the development of therapeutic strategies for the control of their
function.Inthisreview,weillustratethestructuralandfunctionalfeaturesofTLR/IL-1Rproteinsanddiscusssomerecentadvances
in the approaches undertaken to develop anti-inﬂammatory therapeutic drugs. In particular, we will focus on inhibitors, such
as decoy peptides and synthetic mimetics, that interfere with protein-protein interactions between signalling molecules of the
TLR/IL-1R superfamily. Given their central role in innate and adaptive immune responses, it is foreseen that pharmaceutical
modulation of TLR/IL-1R signalling pathways by these drugs might yield clinical beneﬁts in the treatment of inﬂammatory and
autoimmune diseases.
1.Introduction
All living organisms are constantly exposed to pathogenic
microorganisms that are present in the environment. To
face this continuous challenge, evolution has selected mech-
anisms of immune defence to eliminate or counteract
these invading pathogens [1]. In mammals, the immune
response relies on complex strategies of defence consisting
of two components: “adaptive immunity” and “innate
immunity”. Adaptive immunity is a highly sophisticated
system—observed only in vertebrates—characterized by an
exquisite capacity to establish eﬃcient memory responses
to speciﬁc antigens. This system is able to anticipate sub-
sequent encounters with pathogens and represents a potent
defence against microbial infection [2]. Adaptive immunity
is involved in the elimination of pathogens during the late
phase of infection and is elicited by B and T lymphocytes,
which utilize immunoglobulins and T cell receptors, respec-
tively, as antigen receptors to recognize “non self” molecules.
These receptors are generated through DNA rearrangement
and respond to a wide range of potential antigens [3]. In
contrast,the innate immunity, whichwasﬁrstdescribed over
a century ago, is phylogenetically conserved and is present
in almost all multicellular organisms [4]. Innate immunity
represents the ﬁrst line of protection against the invading
microbial pathogens and is mediated by phagocytes, such
as macrophages and dendritic cells (DCs). Although it was
initially viewed as a non speciﬁc response, innate immunity
is indeed able to discriminate between “self” molecules and
a variety of pathogens through the function of a small
array of germline-encoded pattern-recognition receptors
(PRRs). These receptors can speciﬁcally recognize con-
served microbial components known as pathogen-associated
molecularpatterns(PAMPs)[4].ThePRRsincludemembers
of nucleotide oligomerization domain proteins, containing
leucine-rich repeats (NLRs), retinoic acid inducing gene
(RIG)-like helicases (RLHs), and toll-like receptors (TLRs)
[5]. TLRs, which are one of the largest and best studied
families of PRRs, and their signal transduction pathways are
the focus of this review.2 Mediators of Inﬂammation
2. StructuralFeaturesof TLRs
TLRs are evolutionary conserved from plants to vertebrates.
Inmammalsthereare12identiﬁedTLRs[5].Thesereceptors
undergohomo-orheterodimerizationtodetectawiderange
of PAMPs including lipids, lipoproteins, proteins, glycans,
and nucleic acids [6, 7]. Exhaustive reviews covering the
speciﬁcity for diﬀerent ligands recognized by TLRs [8, 9]
as well as the structural features of these receptors have
been recently published [10, 11]. Here we will focus on the
domains that characterize these receptors, with a particular
attention to the TIR domain.
TLRs are characterized by two conserved regions: the
extracellular leucin-rich region (LRR) and the cytoplasmic
Toll/IL-1 receptor (TIR) domain. The LRR, which is deputed
to recognition of the ligand, is composed of 19–25 tandem
repeats of 24–29 amino acids, folded in β-strands and in
α-helices that are linked by loops. The structures of TLR1,
TLR2, TLR3, and TLR4 have been recently solved, leading
to models that predict the mechanism of interaction with
their cognate ligands [11]. The TIR domain, which shares
homology with the interleukin 1 receptor (IL-1R) [12],
is instead responsible for the propagation of the signal
within the cell through interaction with a complex signalling
cascade [8, 9, 13]. Crystallographic analyses of the TIR
domain of human TLR1, TLR2 [10], and TLR10 [14]
revealed that they are composed of ﬁve β-strands alternated
with ﬁve α-helices connected by eight loops (Figure 1).
Moreover, this domain contains three highly conserved
motifs denoted Box 1, 2, and 3 [10]( Figure 1). Box 2 forms
a loop connecting the second β-strand and α-helix, referred
to as the BB-loop. This loop is critical for proper signalling,
as single residue substitutions abolish the ability to recruit
targets without changing the overall fold of the TIR domain
[10]. For instance, a naturally occurring point mutation
(P712H) aﬀecting a conserved proline within the BB-loop is
required for TLR4-triggered downstream signals [15]. This
mutation leads to pathological consequences and renders
C3H/HeJ mice hyporesponsive to lipopolysaccharide (LPS)
[15]. Notably, the homologous point mutation in human
TLR2 (P681H) disrupts the signal transduction induced by
Gram-positive bacteria [16], conﬁrming the critical role of
the BB-loop in TLR signalling.
3. The TLR/IL1-R Superfamily:A Central Role
for the IntracellularAdaptorProteins
In addition to the TLR subfamily, the presence of an intra-
cellular TIR domain is the hallmark of a large group of
proteins that belong to the TLR/IL-1R superfamily [17]
such as the IL-1R subfamily and the TIR-domain-containing
adaptor proteins [17].
The IL-1R subfamily encodes nine members that are
characterized by the presence of extracellular immuno-
globulin-like (Ig) domains and by an intracellular TIR
domain. IL-1R contains three Ig domains and, together with
the highly homologous IL-1R accessory protein (IL-1RAcP),
formsareceptorcomplexforIL-1α,IL-1β and IL−1recep-
tor antagonist (IL-1Ra) [18]. Similarly, the IL-18 receptor
(IL-18R), following binding to IL-18, forms a complex with
IL-18RAcP to initiate downstream signalling. IL-1Rrp2 is
the receptor for the agonists IL-1F6, IL-1F8, and IL-1F9,
which also uses IL-1RAcP as a second chain [19]. Thus,
IL-1RAcP appears to be promiscuous since, in addition to
IL-1RI and IL-1Rrp2, it also associates with ST2, which
has recently been shown to bind IL-33 [20]. IL-1R2 and
SIGIRR are two inhibitory receptors, the former lacks the
TIR domain whereas the latter contains a single Ig domain
for the extracellular segment. The only members that still
remain without any identiﬁed function in this subfamily are
IL-1RAPL and TIGIRR [21].
The third subfamily comprises several adaptor mole-
cules: the Myeloid diﬀerentiation factor 88 (MyD88), the
MyD88-adaptor-like (MAL, also known as TIRAP), the TIR-
domain-containing adaptor protein inducing interferon-β
(IFNβ) (TRIF; also known as TICAM1), the TRIF-related
adaptor molecule (TRAM; also known as TICAM2) and the
sterile α- and armadillo-motif containing protein (SARM)
[12]. These adaptors bridge the TLR/IL-1R receptors to
the intracellular molecules that transduce their signals into
a biological response and play a central role in innate
immunity. Among them, MyD88 is without doubts the most
widely utilised adaptor molecule in TLR/IL-1R signalling. It
was originally identiﬁed as a novel myeloid diﬀerentiation
primary response gene in M1 monoleukemic cell lines [22].
MyD88 has a modular structure consisting of an N-terminal
death domain (DD) separated by a short linker region
from the C-terminal TIR domain [23]. Studies on MyD88-
deﬁcient mice have clearly demonstrated that this protein
is an essential component in the responses to various TLR
ligands,withthesoleexceptionofTLR3[24–26].Thesecond
adaptor in the subfamily to be discovered was MAL/TIRAP.
MAL/TIRAP has a binding domain to phosphatidylinositol-
4,5-bisphosphate (PtdIns(4,5)P2), required for its recruit-
ment to the plasma membrane, at the N-terminus and a TIR
domain at the C-terminus [27, 28]. MAL/TIRAP interacts
with MyD88, and MAL-deﬁcient mice have revealed that this
adaptorisessentialforMyD88-dependentsignallingthrough
TLR2 and TLR4 [29]. TRIF contains consensus TRAF6-
binding motifs (T6BM) in the N-terminal region, a TIR
domain and a receptor-interacting protein (RIP) homotypic
interaction motif (RHIM) in the C-terminal region [30].
TRIF is the only adaptor used by TLR3, and TRIF-mutant
mice display an impaired TLR3-mediated response being
defective in the TLR4-mediated activation of the MyD88-
independent pathway [31]. TRAM contains a TIR domain
in the C-terminal region and functions exclusively in
the TLR4 pathway. The N-terminus of TRAM undergoes
constitutive myristoylation that mediates its association
with membranes. TRAM interacts with TRIF, and TRAM-
deﬁcient mice demonstrated that this protein is also essential
for the MyD88-independent pathway of TLR4 signalling
[32]. Finally, SARM [33], which contains a TIR domain
at C-terminus, two “sterile a” motif (SAM) protein-protein
interactions domains, and an Armadillo repeat motif (ARM)
[34], functions as an inhibitor of TRIF-dependent TLR
signalling [35].Mediators of Inﬂammation 3
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Figure 1: Structure of TIR domains. Sequence alignment of the TIR domains of human TLR1, TLR2, and TLR10 was performed by the
ClustalW2 software. Identical residues are indicated by asterisks, while conservative or semi conservative substitutions are indicated by
double-dots and single-dot, respectively. The TIR domain contains three highly conserved motifs denoted Box 1, 2, and 3 [10]t h a ta r e
shown in open boxes. Grey bars indicate the secondary structure of TIR domains, that are composed of ﬁve β-strands (from βAt oβE)
alternated with ﬁve α-helices (from αAt oαE) connected by eight loops.
4.TLR/IL-1RSignallingPathways
Upon recognition of their cognate ligands, TLR/IL-1R pro-
teins homo- or hetero dimerize (TLR1/2, TLR2/6, IL-1R/IL-
1RacP) and initiate a signalling cascade through recruit-
ment of diﬀerent combinations of TIR-domain-containing
adaptor protein to their TIR domain, in order to turn
on both common and unique pathways (Figure 2). All
receptors of the superfamily, with the sole exception of
TLR3, use MyD88 to initiate their signalling pathway. In
some cases, MyD88 acts in concert with other adaptors,
like MAL/TIRAP in the response triggered by stimulation of
TLR4, TLR1/2, and TLR2/6 [12]. On the other hand, TLR3-
mediatedsignallingrequiresonlytheadaptormoleculeTRIF,
which is also recruited by TLR4 in association with the
other adaptor TRAM [12]. Based on the type of adaptor
molecules involved, the TLR/IL-1R-induced pathways can be
sub-grouped in two classes: MyD88-dependent and MyD88-
independent responses.
5. MyD88-DependentSignalling
The MyD88 TIR domain diﬀers from the TIR domain of
TLRs, as it contains ﬁve central β-strands surrounded by
four α-helices instead of ﬁve α-helices [36]( Figure 3(a)).
TLR/IL-1R receptors associate with MyD88 through homo-
typic interactions between their respective TIR domain.
This interaction then allows MyD88 to recruit members of
the interleukin-1 receptor-associated kinase (IRAK) family
(IRAK1, IRAK2, and IRAK4) through homotypic interac-
tions between their respective Death Domains (DDs) [38]
(Figure 2). Notably, recent studies have identiﬁed critical
residues in MyD88 DD required for association with either
IRAK1 or IRAK4 (Figure 3(b))[ 37]. Since their substitution
impaired propagation of the downstream signaling response
[37], it is likely that these interactions are necessary. The
interaction between MyD88 and IRAK1/4 induce the forma-
tion of macromolecular complexes that ultimately impinges
on TAK1 (transforming growth factor β-activated kinase 1)
[39] and leads to activation of the transcription factor NF-
κB (p50/p65) [8, 9, 17, 40]( Figure 2). However, MyD88-
dependent activation of NF-κB can also be induced by
TAK1-independent pathways, as shown by the incomplete
suppression of IL-1- or LPS-induced NF-κBa c t i v a t i o ni n
TAK1-deﬁcient murine embryonic ﬁbroblasts [41]. Two
candidates for this TAK1-independent pathway are the
mitogen-activated protein kinase kinase kinase 3 (MEKK3)
and Protein kinase C (PKC) [42, 43].4 Mediators of Inﬂammation
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Figure 2: TLR/IL-1R signalling pathways. Once activated by their respective ligands, IL-1R, IL-18R, and TLRs engage with one or more
adaptorproteins.Theseadaptors,namely,MyD88,MAL/TIRAP,TRIF,andTRAMarerecruited,invariouscombinations,tothecytoplasmic
domains of the receptors through homophilic interactions between Toll/IL-1 receptor (TIR) domains present in each receptor and each
adaptor. TIRAP is required to act as a bridge for MyD88 in TLR2 and TLR4 signalling, while TRIF is used in TLR3 signalling and, in
associationwithTRAM,inTLR4signalling.IntheMyD88-dependentpathway,MyD88associateswithIRAK4,IRAK1and/orIRAK2.IRAK4
in turn phosphorylates IRAK1 and IRAK2 and promotes their association with TRAF6, which serves as a platform to recruit the kinase
TAK1. Once activated, TAK1 activates the IKK complex, composed of IKKα,I K K β and NEMO (IKKγ),which catalyzes phosphorylation
and subsequent degradation of IκB rendering NF-κB (i.e., p50/p65) free to translocate from the cytosol to the nucleus and activate NF-κB-
dependent genes. The transcription factor IRF7 is also activated downstream of TLRs 7, 8, and 9, leading to its translocation into the nucleus
and to activation of IFNα and IFN-inducible genes. TLR3 and TLR4 both signal through the adaptor TRIF, which interacts with TRAF3
to activate the noncanonical IKKs, TBK1, and IKKε resulting in the dimerization and activation of IRF3, which then translocates into the
nucleus activating the transcription of IFNβ and IFN-inducible genes.
TAK1 can also activate mitogen-activated protein kinases
(MAPKs), such as p38 and JNK, leading to the activation
of transcription factor AP-1 [44]. The concomitant activa-
tion of NF-κB and AP-1 induces a pleiotropic inﬂamma-
tory response through the production of proinﬂammatory
cytokines [44]. In addition, MyD88-dependent signalling
downstream of TLR7 and TLR9 elicits the induction of IFN-
α [44]. This response is speciﬁc to plasmacytoid dendritic
cells(pDC),whichexpresshighlevelsofTLR7andTLR9and
p r o d u c eh i g hl e v e l so fI F N - α. Upon ligand stimulation, the
TIRdomainsofTLR7andTLR9recruitacomplexconsisting
of MyD88, IRAK-4, IRAK-1, and TRAF6 [45], which binds
and activates the transcription factor IRF-7 thereby inducing
expression of type I IFN (IFN-α and IFN-β)[ 46].
In summary, the small adaptor MyD88 is at the
crossroad of several signalling routes triggered by noxious
agents through TLR/IL-1R receptors. For this reason, it is
envisioned as a potential target to downregulate excessive
immune responses. At the same time, its involvement in
so many physiological responses is a challenge for the
developmentofanti-inﬂammatorytherapeuticagentsdevoid
of potentially dangerous side-eﬀects.
6. MyD88-Independent Signalling
Several observations have indicated the presence of MyD88-
independent TLR/IL-1R signalling pathways. Although
MyD88-deﬁcient cells do not express several inﬂammatory
cytokines upon LPS stimulation, activation of NF-κBa n d
JNK is only delayed [25]. Furthermore, induction of type I
IFNs is not impaired [47]. The best characterized MyD88-
independent pathway is that triggered by TLR3, which
requires only TRIF as adaptor [48]. On the other hand,
recruitment of TRAM is required to bridge TRIF to TLR4
(Figure 2). Thus, TLR4 is capable of activating both MyD88-
dependent and TRIF-dependent signalling pathways, in aMediators of Inﬂammation 5
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Figure 3: Schematic representation of the TIR and Death Domains
of MyD88. (a) A schematic representation of the human MyD88
TIR domain. The TIR domain of MyD88 consists of ﬁve central β-
strands surrounded by four α-helices, connected by loops [36]. It
lacks the α-helix αD in the region between βDa n dβE strands, this
region has an helical coil conformation. (b) Surface of interaction
of the MyD88 Death Domain with IRAK1 and IRAK4. The
region MyD88 Death Domain (DD) comprised by residues 27–72
(predicted α1, α2, α3 and N-terminal α4 helices) is required for the
recruitment of IRAK1 [37] .R e s i d u e sE 5 2a n dY 5 8o fM y D 8 8D D
are implicated in the interaction of IRAK1 with MyD88. Moreover,
residue K95 in the predicted α5 helix is involved in the recruitment
of IRAK4 by MyD88 DD.
sequential process that involves the endocytosis of the TLR4
complex [49]. In particular, TLR4 ﬁrst induces MAL/TIRAP-
MyD88 signalling at the plasma membrane. Then, following
its endocytosis into early endosomes, TLR4 activates TRAM-
TRIF signalling. Once recruited to the receptor, TRIF inter-
acts with TRAF3 to activate the noncanonical IKKs TBK1
and IKKε resulting in activation of IRF3 and transcription
of IFNβ and IFN-inducible genes [50]( Figure 2).
The more limited spectrum of action of these additional
adaptors suggests that speciﬁc inhibitors of their function
might exert a more selective anti-inﬂammatory response. On
the other hand, the eﬃcacy of such compounds might also
be more limited than MyD88 inhibitors. Thus, it is at the
momentunclearwhichmemberoftheTLR/IL-1Rsuperfam-
ily is the most suitable target for pharmaceutical approaches.
7. Inhibition of TLR /IL1-R Function As a
Therapeutic Approach
The central role of the members of the TLR/IL-1R super-
family in the immune response is highlighted by their
implication in inﬂammatory and immune disorders such
as sepsis syndrome, asthma, atherosclerosis, Alzheimer’s
disease, rheumatoid arthritis (RA) [21, 51]. Moreover, on
a susceptible genetic background, TLR signalling can also
induce autoimmune diseases such as Systemic Lupus Erythe-
matosus (SLE), Multiple Sclerosis (MS), and Inﬂammatory
Bowel Diseases (IBD) [52]. For these reasons, therapeutic
targeting of TLR/IL-1R signalling is gaining more and more
attention as a potentially valuable approach for many dis-
eases of the immune system. Herein, we illustrate some novel
strategies utilized for the development of anti-inﬂammatory
therapeutics based on interference with the function of the
TIR domain of members of the TLR/IL-1R superfamily.
One approach to modulate the activity of TLRs is the
inhibition of intracellular proteins involved in the signalling
pathways triggered by multiple receptors [53]. This view has
been criticized on the ground that global inhibition of TLR
signallingmightbedeleterious,asitcouldleadtoareduction
in the body’s defences against pathogens [54]. However,
recent evidence suggests that the redundancy of mammalian
host’s immune responses together with the high degree of
cross-talk between TLR-initiated signalling pathways might
allow to overcome a generalized block in the immune
response[55].Forinstance,childrenwithrecurrentpyogenic
infections display inactivating mutations in either the DD or
TIR domain of MyD88 that render the patients vulnerable
to S. pneumoniae, S. aureus,a n dP. aeruginosa.H o w e v e r ,
these patients are normally resistant to most common
bacteria, viruses, fungi, and parasites [56]. Thus, although
MyD88 is involved in almost all TLR signalling pathways,
suppression of its function does not cause a complete block
in the immune response. Similar ﬁndings were reported with
IRAK-4-deﬁcient patients [57]. Albeit these deﬁciencies are
life-threateninginthechildhood—withabout40%mortality
in the ﬁrst eight years of life—they progressively become
less severe with age. Indeed, no deaths or invasive infections
were observed in patients over the age of 8 and 14 years,
respectively [58]. The improved clinical status was not due
toanyleakinessin MyD88andIRAK-4deﬁciency,suggesting
thattheMyD88-dependentTLR/IL-1Rsignallingplaysavital
role early in life, but becomes less important for survival
during ageing. This is likely consequent to activation and/or
maturation of TLR-independent innate immunity [9, 59–
62]. Moreover, these ﬁndings seem to suggest that innate
immunity is more important upon the very ﬁrst encounter
with a pathogen. Once adaptive immunity is generated,
however, resistance to infection becomes quite eﬃcient even
in the absence of crucial functional components of TLR
signalling [63].
TLR-mediated signalling is of paramount importance
in eradicating microbial infections and promoting tissue
repair. Nevertheless, it must be tightly regulated [67]i n
order to prevent a sustained, overzealous activation that
might set the ground for autoimmune and inﬂammatory6 Mediators of Inﬂammation
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Figure 4: Chemical Structure of TIR BB-Loop Mimetic Compounds. AS1 (a), EM77 (b), and EM110 (c) inhibit the association between
IL-1R and MyD88 [64, 65]. ST2825 (d) inhibits MyD88 homodimerization and its interaction with IRAK1 and IRAK4 [66].
disorders [68, 69]. Therefore, therapeutic agents targeting
the TLR signalling must be able to antagonize the harmful
eﬀects resulting from TLR hyperactivation while sparing
their properly operating functions in host-defence. In spite
of these apparent obstacles, evidence is accumulating that
drugs targeting TLRs and their signalling adaptors can
provide new therapeutic opportunities to prevent or treat
human inﬂammatory and autoimmune diseases [70–72].
Herein, we will focus on approaches aimed at developing
rationally-designed inhibitors (Figure 4) that interfere with
protein-protein interactions of adaptor-adaptor or adaptor-
TLR complexes. The readers are referred to several recent
reviews that discuss additional approaches that are currently
under development to target TLR function [73–76].
8. Targeting the TIR BB-Loop for Development
of Novel TLR/IL1-R SignallingInhibitors
Protein-protein interactions are central to most biological
processes, suggesting that interfering with speciﬁc interac-
tions might aﬀect cellular responses. Nevertheless, develop-
ing small molecules that modulate these interactions may
not be an easy task, due to typical ﬂatness of the interface
of contact between proteins and because large surface areas
are usually involved [77, 78]. However, despite this approach
presents a major challenge in terms of therapeutic feasibility,
initial steps have been taken with the design of peptide-based
inhibitors.
The TIR domain of TLR/IL-1R proteins is a putatively
suitable target. In particular, the BB-loop region may be
regarded as a critical functional interface of TIR domain for
its critical role in proper signalling [10, 15, 79].
9.BB-Loop Decoy Peptides
Decoy peptides are short amino acid sequences of a protein
that are expected to mimic its interaction surface and to pre-
ventinteractionoftheprototypeproteinswiththeirpartners.
Several reports have shown the successful realization of this
concept, and a number of decoy peptides binding to BB-
loops were found to inhibit TLR/IL-1R signalling.
A TIRAP decoy peptide consisting of the 14 amino
acid-long sequence in the BB-loop (LQLRDAAPGGAIVS),Mediators of Inﬂammation 7
fused to the Drosophila antennapedia homeodomain to
facilitate the intracellular delivery [80], speciﬁcally blocked
TLR4-induced activation of NF-κB without aﬀecting the
TIRAP-independent TLR9 response [27]. In vivo adminis-
tration of TIRAP inhibitory peptide counteracted the lung
inﬂammatory response in healthy C57BL/6 mice [81]. The
peptide abolished LPS-induced TNF-alpha, IL-6, and IL-8
expression in alveolar macrophages, whereas it attenuated E.
coli-induced expression of these cytokines and chemokines
[81]. These results have suggested new therapeutic options
for TIRAP inhibitors in the treatment of acute lung injury
and acute respiratory distress syndrome.
Similarly, BB-loop heptapeptides derived from MyD88
and IL-18R inhibited homomeric interaction of MyD88 TIR
domain or full-length MyD88 in vitro [82]. These peptides
exerted a speciﬁc eﬀect, because heptapeptides derived
from BB-loop of other TLR/IL-1R proteins were either
less eﬀective (TLR1) or completely inactive (IL-1RAcP).
Moreover, a cell permeable derivative of the MyD88 BB-
loop decoy heptapeptide (RDVLPGT) signiﬁcantly reduced
IL-1-induced NF-κB reporter activity and blocked MyD88
homomeric interaction in live cells [82]. A number of
studies have conﬁrmed the activity of this construct in
diﬀerent experimental settings. For instance, this MyD88
inhibitory peptide signiﬁcantly suppressed HMGB1-induced
IL-23 release in alveolar macrophages by signiﬁcantly
inhibiting IRAK4 activation [83]. It was also found that this
decoy peptide diminished MyD88-dependent MMP-13 gene
expression, phosphorylation of MAPKs, and AP-1 activity in
normal human knee articular chondrocytes [84], suggesting
a possible application of this approach to treatment of RA.
Moreover, the MyD88 inhibitor peptide speciﬁcally reduced
TNF-α production and Poly(g-Glutamic acid) nanoparticles
(NPs)-induced DC maturation [85]. Other authors reported
that preincubation of professional antigen-presenting cells
(APCs) with this molecule almost completely inhibited
induction of CD80 expression by either human β-defensin-
3, an antimicrobial peptide, or LPS. Remarkably, the MyD88
inhibitorypeptidehadminimalandnonsigniﬁcanteﬀectson
costimulatory molecule induction by IFN-α, indicating its
speciﬁc action in TLR-induced APC diﬀerentiation [86].
By following the same experimental approach, Toshcha-
kov and colleagues performed systematic investigations of
decoy cell permeable peptides containing TIR domain BB-
loop sequences derived from the adaptor proteins MyD88,
TIRAP, TRAM, and TRIF as well as the receptors TLR1,
2, 4, and 6 [87–89]. These decoy peptides were all able to
inhibit, with varying activity, the TLR signalling pathways
[88]. Although the TLR2 and TLR4 decoy peptides also
showedsomedegreeofcross-reactivity,theydidnotinterfere
with TLR3 signalling [89]. Notably, BB-loops of TLR4 and
TLR3 share only ﬁve identical amino acids, with proline 712
present in TLR4 but not conserved in TLR3, hence providing
a possible structural base for the lack of eﬀects of TLR2- and
TLR4- derived decoy peptides toward TLR3 signaling.
Thus, the studies reported above highlight the possibility
to produce inhibitory drugs that interfere with protein-
protein interactions in the TLR/IL-1R signalling pathways.
10.BB-Loop Peptidomimetics
The BB-loop decoy peptides may also represent a valuable
starting point to produce synthetic small molecules that
mimic the structure of target proteins, hence paving the way
for developing novel therapeutic agents.
Bartfai and colleagues were the ﬁrst to show that the BB-
loopregionoftheTIRdomainwasamenabletodevelopment
of selective synthetic inhibitors of protein-protein interac-
tions. By focusing on TIR-domain interactions between IL-
1RI and MyD88, they synthesized a low-molecular-weight
moleculemimetic,hydrocinnamoyl-L-valylpyrrolidine.This
molecule is based upon the protruding three amino acid
residues of the MyD88 BB-loop, which mimic the (Phe/Tyr)-
(Val/Leu/Ile)-(Pro/Gly) sequence [64], consensus for several
TLR/IL-1R family members [90]. This mimetic compound
blocked IL-1β-induced phosphorylation of the mitogen-
activated protein kinase p38 in EL4 thymoma cells [64].
Moreover, sandwich ELISA assays demonstrated that this
compound inhibits the IL-1β mediated association of IL-
1R1 and MyD88 in both EL4 cells and in freshly isolated
lymphocytes from mouse spleen. The disruption of the IL-
1RI-MyD88 interaction was also shown to be selective over
other TLR members. Remarkably, the inhibitory eﬀects on
IL-1β-signaling were conﬁrmed in vivo, as mice treated with
200mg/kg of the compound exhibited signiﬁcant attenua-
tion of the IL-1β-induced fever response [64] .T h es a m eT I R
BB-loop mimetic was investigated in vivo in a myocardial
ischaemia model, and it was shown to decrease infarct size
by ∼33% and to improve ejection fraction and fractional
shortening in treated mice [91]. These results suggested
that modulation of the IL-1R/MyD88 interaction could be
a strategy for reducing myocardial ischaemic injury, and
additional recent investigations support this notion [92, 93].
Based on this compound, Bartfai and colleagues synthe-
sized a novel series of bifunctional BB-loop mimetics. Their
rationale stemmed from the assumption that bifunctional
compounds might be more eﬀective blockers of protein-
protein interactions than monofunctional compounds [94].
They reported that two such mimetic compounds, EM77
andEM110,possessedantinﬂammatoryandneuroprotective
properties. They inhibited MyD88-dependent proinﬂamma-
tory action of IL-1β without aﬀecting activation of the
kinase AKT/PKB, which depended on PI3-kinase activation
through binding to IL-1R [65]. The selectivity of action
of the MyD88 BB-loop mimetics toward the two pathways
activated by IL-1β in primary cultures of preoptic area
(POA)/AH neurons allowed the authors to suggest that
they may exert antinﬂammatory eﬀects while concomitantly
promoting neuronal survival in the nervous system.
The MyD88 BB-loop heptapeptide [82] also served as a
template for the design and synthesis of a peptidomimetic
library [95]. The RDVLPGT (Arg-Asp-Val-Leu-Pro-Gly-
Thr) region was subdivided into three distinct portions:
a charged portion (Arg-Asp amino acids), a hydrophobic
portion (Val-Leu amino acids), and a β-turn portion
(Leu-Pro-Gly-Thr amino acids). A peptidomimetic library
consisting of 4368 direct and 234 retroinverse mimetics
was designed by combining all these building blocks. For8 Mediators of Inﬂammation
practical reasons, a subset of 83 compounds selected from
the library was prepared on solid phase by using a polymer
supported (aminomethyl) polystyrene (Rink amide) resin
[95]. All selected compounds for synthesis met the “rule
of ﬁve” [96]. The ability of the peptidomimetics to inhibit
protein-protein interaction was ﬁrst assessed by a yeast 2-
hybrid assay [95]. Active compounds were then further
validated in a mammalian cell system by evaluating the
inhibition of MyD88-dependent NF-κB activation. One of
the most eﬀective compounds, termed ST2825, inhibited
homomeric interaction of MyD88 TIR domains [66]. This
eﬀect was speciﬁc for TIR domains and did not aﬀect
interaction of MyD88 DDs. Moreover, ST2825 blocked
recruitment of IRAK1 and IRAK4 by MyD88, leading to
inhibition of IL-1β-mediated NF-κB activation. ST2825 also
blocked TLR9-elicited signalling pathways by suppressing
B cell proliferation and diﬀerentiation into plasma cells
in response to CpG. Additionally, oral administration of
ST2825 in mice dose-dependently inhibited IL-1β-induced
production of IL-6 [66]. Finally, ST2825 intraperitoneal
administration signiﬁcantly protected against left ventricular
(LV) enlargement in a permanent ligation model of acute
myocardial infarction in mice [97].
These ﬁndings [91, 97] suggest that MyD88 inhibition
may represent a completely novel approach for future
translationalinvestigationsforthepreventionofheartfailure
following acute myocardial infarction [98]. Nevertheless, a
generalised suppression of MyD88 function might cause
unwanted side eﬀects, especially in chronic diseases that
require continuous treatments. Thus, a controlled sup-
pression may prove to be a viable therapeutic approach
in an anti-inﬂammatory therapy once an inﬂammatory
condition is presented. This notion is supported by studies
conducted using RDP58, a novel anti-inﬂammatory d-
amino acid decapeptide that inhibits the MyD88 pathway
by disrupting the formation of the MyD88/IRAK4/TRAF6
complex [99]. Indeed, early human trials have shown
an improvement in mild-to-moderate ulcerative colitis
[100], and RDP58 is currently being developed in clini-
cal trials for IBD (http://www.genzyme.com/corp/licensing/
genz p rdp58 login.asp).
11. Conclusions
A tremendous progress has been made over the past
several years in elucidating signalling pathways involved in
inﬂammatory disorders, pointing to NF-κB as the crucial
downstream player. An immediate and transient activation
of NF-κB is important for the normal physiological response
to pathogenic damage, but its persistent and excessive activa-
tion is conducive to development and progression of cancer
and chronic inﬂammatory disorders [101, 102]. Although
much emphasis has been placed on the development of NF-
κB inhibitors [103], generic inhibition of NF-κBm a yl e a d
to undesired side eﬀects. Hence, a challenging objective is
to develop drugs that block its eﬀects in speciﬁc pathways,
while leaving its physiological functions in other contexts
largely intact. TLR/IL-1R pathways seem to respond to these
requirements. They represent attractive targets for anti-
inﬂammatory drug discovery, because their inhibition may
impair a subset of noxious inﬂammatory signals impinging
on NF-κB, while sparing its normal physiological activation
[104]. Blockade of adaptor proteins connected to these
signalling pathways, such as MyD88, is expected to be more
eﬀectivethaninhibitionofindividualligandactivities,dueto
the mechanistic sharing of a common transduction pathway
[53, 55]. In particular, the blockade of TIR-TIR interactions
between various members of the TLR/IL-1R superfamily
provides new opportunities in light of the highly conserved
nature of the TIR domain.
Althoughseveralreportshaveshedlightonthestructures
of TIR domains from human TLR/IL-1R proteins [10, 14,
105], Protein Data Bank (PDB) IDs: 2JS7; 2Z5V, their
homomeric and heteromeric interactions have not been fully
elucidated yet. Recent investigations suggest that following
ligand-induced interaction of TIR-containing receptors a
multi-TIR complex may form upon recruitment of multiple
cytoplasmic adaptors [37, 106]. A major goal is the devel-
opment of speciﬁc antagonists able to dismantle assembly of
thesesignallingplatforms.Despitesuchanapproachpresents
daunting challenges in terms of therapeutic feasibility, initial
steps have been taken by designing inhibitor decoy peptides
that block the function of adaptors [81, 82]. However, it has
to be underlined that these peptides will unlikely form per
se the basis for new drugs, but chemists may use them as
templates to develop peptidomimetics or other compounds.
The recent identiﬁcation [64, 66, 94] of a few TIR mimetics
(Figure 4) allows to envision that design of further selective
inhibitors of TIR-domain-containing proteins may be within
reach.Yet,determininghowtomaintainthebalancebetween
host-defence functions and the undesired eﬀects that may
result from TLR inhibition remains a serious issue for those
designing new therapeutics. Additional clinical experience
with these novel molecules might allow to establish their
relative safety and eﬃcacy in human beings. Hopefully, these
novel therapeutics may not only ﬁnd application in acute
settings, such as septic shock, but also in the treatment of
autoimmunedisorderscharacterisedbyrecurrentepisodesof
inﬂammatory ﬂares.
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